What a cool idea

The wide adoption of CAR T therapies has been prevented by cost ($500K/patient) and complexity (2 weeks in a GMP-manufacturing facility).

Persistence reduces the time and cost of CAR T therapies by creating synthetic lymph nodes that are made outside the patient and then implanted using a minimally invasive procedure.

Imagine drugs engineered to accumulate at sites of disease to exert tissue-selective biology. Cavalry has created medicines that target the growth plate, muscle fibers, and secretory glands.

Cavalry expects to have two pIND meetings with the FDA in 2024, with one drug entering the clinic in 2025 and a second in 2026.